BusinessKura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539By Nasdaq OMXApr 5, 2017, 12:01 PM UTC
BusinessFibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDSBy Nasdaq OMXMar 31, 2017, 11:05 AM UTC
BusinessPreclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017By Nasdaq OMXMar 29, 2017, 11:33 AM UTC
BusinessKura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial ResultsBy Nasdaq OMXMar 14, 2017, 8:05 PM UTC
BusinessKura Oncology to Report Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXMar 7, 2017, 9:05 PM UTC
BusinessKura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for TipifarnibBy Nasdaq OMXMar 6, 2017, 12:30 PM UTC
BusinessKura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017By Nasdaq OMXFeb 27, 2017, 12:30 PM UTC
BusinessKura Oncology to Participate in Three Upcoming Investor ConferencesBy Nasdaq OMXFeb 9, 2017, 9:07 PM UTC
